Improving the lives of people suffering from mental illness and substance use disorders

What we do

Pharmaceuticals

Pharmaceuticals

Commercializing and developing of pharmaceuticals addressing large unmet needs

Digital Therapeutics

Digital Therapeutics

Product portfolio of scientifically proven digital therapies

Mental illness & substance use disorders

Mental illness & substance use disorders

Focusing on areas of great human suffering with wider societal implications

MODIA™ - our digital therapy for opioid dependence

  • to be used along with pharmaceuticals
  • 6 months treatment
  • grounded in cognitive behavioral therapy techniques
  • available 24/7
  • ongoing clinical trial incl. up to 400 patients

Key News

JANUARY 21, 2022
Presentation of the Q4 Interim Report on January 27 at 2 pm CET

DECEMBER 22, 2021
Robert Rönn, SVP and Head of R&D: My vision is to develop several new drugs based on amorphOX™

DECEMBER 2, 2021
Orexo develops a nasal adrenaline medication based on the novel amorphOXTM platform

Orexo Social

20 January 2022

Next week on January 27 we will announce the Q4 Report. The same day we invite to a call where members of Orexo´s m… https://t.co/nNS5qF8Gvj

18 January 2022

Today we look forward to have Mikaela Odlander, Director & head of Digital Therapeutics EMEAA, joining a panel sess… https://t.co/L5UcDg8h5y

12 January 2022

We’re hiring! By joining our US SALES FORCE you’ll experience unique opportunities to make a difference to people’s… https://t.co/4qfKI632qF

Our history

Strong history paving the way for the future. Learn more about our key milestones since we where founded in Uppsala, Sweden, in 1995.

Financial Snapshot

Group net revenues

580 MSEK

LTM1

Group EBITDA

-112 MSEK

LTM1

US Pharma segment EBIT

301 MSEK

LTM1

Cash position

588 MSEK

Q3 2021

1 Last Twelve Months, Q420-Q321, for more information about financial development Link